|
News
February 13, 2006
Funding of new grant award of $2 million for 4 years by
USAMRAA PRMRP (PR054755: "Novel Nitroxide Resuscitation Strategies in
Experimental Traumatic Brain Injury", a collaborative project between Safar Center for Resuscitation Research and
SynZyme Technologies LLC)
January 27, 2006
Publication of a manuscript by scientists in the Department
of Medicine at Albert Einstein College of Medicine and at SynZyme entitled “Inhibition of Sickle Red Cell
Adhesion and Vaso-occlusion in the Microcirculation by Antioxidants” in the Am J Physiol Heart Circ Physiol showing PNA”s potential to
ameliorate sickle (SS) red cell adhesion and the related vaso-occlusion in
sickle cell disease.
January 20, 2006
Meeting with the FDA
regarding VACNO® for Exploratory
IND
October 6 2005
Opened a production
facility for SynZyme drug intermediates in TainJin, China
September 12 2005
Selected to
participate in NIH-CAP program
July 27, 2005
Funding of new grant award to SynZyme Technologies LLC of $3 million
for 3 years by NINDS (2R44NS036119-04: “PNA for Stroke”)
April 27
2005
Publication of a manuscript entitled “Polynitroxyl albumin
inhibits inflammation and vasoocclusion in transgenic sickle mice” in the J Lab Clin Med. (vol 145(4): pg 204-11) showing PNA’s possible efficacy to prevent painful
vaso-occlusion in sickle cell disease.
February 2, 2005
Pre-IND Meeting with
the FDA regarding HemoZyme® development
November 23, 2004
Granted extension of US the Army grant for “Polynitroxyl Albumin
plus Tempol (PNA + Tempol) for Combat Casualty Care: Phase I Human Trial”
October 27, 2004
Pre-IND meeting with
FDA regarding VACNO® for stroke
May 6, 2004
Pre-IND meeting with
FDA regarding VACNO® for Sickle Cell Disease
|
